IDA-FLAG (idarubicin, fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor) - An effective regimen in relapsed acute myelogenous leukemia in childhood;IDA-FLAG (IDARUBICIN, FLUDARABIN, HOCHDOSIERTES CYTARABIN UND G-CSF) - EIN EFFEKTIVES THERAPIESCHEMA IN DER BEHANDLUNG VON AML-REZIDIVEN BEI KINDERN UND JUGENDLICHEN

Klinische Padiatrie

Volumn 208, Issue 4, 1996, Pages 229-235

  Fleischhack, Gudrun ^a   Graf, Norbert ^b   Hasan, Carola ^a   Ackermann, Matthias ^c   Breu, Herbert ^d   Zernikow, Boris ^a   Bode, Udo ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c Amgen Research GmbH   (Germany)

^d KLINIKUM DORTMUND   (Germany)

Author keywords

AML; Cytarabine; Fludarabine; Relapse

Indexed keywords

CYTARABINE; FLUDARABINE; FLUDARABINE PHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ARTICLE; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOXICITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PROGNOSIS; RECURRENT DISEASE;

EID: 0030055969     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1046478     Document Type: Article

References (39)

1. Baer, M. R., N. P. Christiansen, S. R. Frankel, V. L. Brunetto, K. Mrózek, C. D. Bloomfield, G. P. Herzig: High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. Semin. Oncol. 20. Suppl. 8 (1993) 6-12
2. Bhalla, K., A. M. Ibrado, C. Holladay, G. Bullock: Hemopoietic growth factors (HGFs) G-CSF and IL 3 improve the antileukemic selectivity of high-dose ARA-C (HIDAC). Blood 78, Suppl. 1 (1991) 425
3. Carella, A. M., E. Pungolino, G. Platti, E. Gaozza, S. Nati, M. Spriano, D. Giordano, T. D'Amico, E. Damasio: Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias. Eur. J. Hematol. 43 (1989) 309-313
4. Carrera, C. J., A. Saven, L.D. Piro: Purine metabolism of lymphocytes. Targets for chemotherapy drug development. Hematol. Oncol. Clin. North Am. 8 (1994), 357-381
5. Cheson, B. D., D. A. Vena, F. M. Foss, J. M. Sorensen: Neurotoxicity of purine analogs: A review. J. Clin. Oncol. 12 (1994) 2216-2228
6. De Witte, T., P. Muus, M. Peetermans, P. Fenaux, P. Skijkmans, B. Jacsic, S. Suciu, G. Solbu, R. Zittoun: A pilot study of intensive remission induction chemotherapy for bad prognosis myelodysplastic syndromes (MDS) and acute myelogenous leukemia secondary (sAML) to MDS of more than six months duration. Blood 80 (1992) 209a
7. Estey, E., W. Plunkett, V. Gandhi, M. B. Rios, H. Kantarjian, M. J. Keating: Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia and Lymphoma 9 (1993a) 343-350
8. Estey, E., S. Pierce, H. Kantarjian, S. O'Brien, M. Beran, M. Andreeff, S. Escudier, C. Koller, S. Kornblau, L. Robertson, M. Keating: Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leukemia and Lymphoma 11, Suppl. 2 (1993b) 59-63
9. Estey, E., V. Gandhi, M. J. Keating: G-CSF potentiates clinical and pharmacokinetic response to fludarabine and ara-C in AML and MDS. Proc. Am. Soc. Clin. Oncol. 12 (1993c) 301
10. Estey, E., P. Thall, M. Andreeff, M. Beran, H. Kantarjian, S. O'Brien, S. Escudier, L. E. Robertson, C. Koller, S. Kornblatt, S. Pierce, E. J. Freireich, A. Deisseroth, M. Keating: Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol. 12 (1994) 671-678
11. Feldman, E., V. Gandhi, W. Plunkett, B. Novak, E. Estey, H. Kantarjian, S. O'Brien, M. B. Rios, M. J. Keating: Sequential administration of fludarabine, ara-C, and mitoxantrone enhances topoisomerase II-DNA complex formation and has efficacy in acute leukemia. Blood 80 (1992) 208a
12. Gandhi, V., W. Plunkett: Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 48 (1988) 329-334
13. Gandhi, V., W. Plunkett: Interaction of arabinosylnukleotides in K562 human leukemia cells. Biochem. Pharmacol. 38 (1989) 3551-3558
14. Gandhi, V., E. Estey, M. J. Keating, W. Plunkett: Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 11 (1993a) 116-124
15. Gandhi, V., E. Estey, M. J. Keating, W. Plunkett: Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leukemia and Lymphoma 10 (1993b) 109-114
16. Harousseau, J. L., J. Reiffers, P. Hurteluop, N. Milpied, H. Guy, F. Rigal-Huguet, T. Facon, P. Dufour, N. Ifrah: Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. J. Clin. Oncol. 7 (1989) 45-49
17. Hiddemann, W., H. Kreutzmann, K. Straif, W. D. Ludwig, R. Mertelsmann, R. Donhuijsen Ant, E. Lengenfelder, Z. Arlin, T. Büchner: High-dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia. Blood 69 (1987) 744-749
18. Huang, P., W. Plunkett: Cell cycle-dependent apoptosis induced by nucleoside analogues. Proc. Am. Assoc. Cancer Res. 33 (1992) 151
19. Huang, P., W. Plunkett: Replicon-sized DNA fragmentation induced by nucleoside analogues. Proc. Am. Assoc. Cancer Res. 34 (1993) 289
20. Hurwitz, C. A., K. G. Mounce, H E. Grier: Treatment for patients with acute myelogenous leukemia: Review of clinical trials of the past decade. J. Pediatr. Hematol. Oncol. 17 (1995) 185-197
21. Keating, M. J., S. O'Brien, L. E. Robertson, H. Kantarjian, M. Dimopoulos, P. McLaughin, F. Cabanillas, V. Gregoir, L.-Y. Yang, Y. Gandhi, E. Estey, W. Plunkett: New initiatives with fludarabine monophosphate in hematologic malignancies: Semin. Oncol. 20. Suppl. 7 (1993) 13-20
22. Koistinen, P., C. Wang, G. S. Yang, Y.-F. Wang, D. E. William, S. D. Lyman, M. D. Minden, E. A. McCulloch: Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity. Leukemia 5 (1991) 789-795
23. Plunkett, W., P. Huang, V. Gandhi: Metabolism and action of fludarabine phosphate. Semin. Oncol. 17, Suppl. 8 (1990) 3-17
24. Plunkett, W., P. P. Saunders: Metabolism and action of purine nucleoside analogs. Pharmacol. Ther. 49 (1991) 239-268
25. Plunkett, W., V. Gandhi, P. Huang, L. E. Robertson, L.-Y. Yang, V. Gregore, E. Estey, M. J. Keating: Fludarabine: Pharmacokinetics, mechanism of action, and rationales for combination therapies. Semin. Oncol. 20. Suppl. 7 (1993a) 2-12
26. Plunkett, W., E. Estey, V. Gandhi: Interactions of granulocyte colony-stimulating factor and nucleoside analogs. Exp. Hematol. 21 (1993b) 1033
27. Rayappa, C., E. A. McCulloch: A cell culture model for treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside. Leukemia 7 (1993) 992-999
28. Ritter, J., U. Creutzig, G. Henze, H. Jürgens, U. Bode, G. Prindull, G. Schellong: Hochdosiertes ARA-C in Kombination mit Mitoxantron bei der Therapie der AML im Kindesalter. Erste Ergebnisse der AML-Rezidivstudie BFM-85. Onkologie 10 (1987) 24-27
29. Ritter, J., U. Creutzig, G. Schellong: Treatment results of three consecutive German childhood AML trials: BFM -78, -83, and -87, Leukemia 6, Suppl. 2 (1992) 59-62
30. Ritter, J., U. Creutzig, M. Zimmermann: The specific role of idarubicin during induction therapy of childhood AML. Ann. Hematol. 70, Suppl. II (1995) A99
31. Santana, V. M., J. Mirro, F.C. Harwood, J. Cherrie, M. Schell, D Kalwinsky, R. L. Blakley: A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J. Clin. Oncol. 9 (1991) 416-422
32. Sato, J. K., S. Wiersma, M. Krallo, B. Bostrom, S Shurin, A. Cheerva, D. Hammond, V. Avramis: Phase I Clinical and pharmacodynamic study of continuous infusion (Cl) fludarabine followed by continuous infusion (Cl) cytosine arabinoside (ara-C) in relapsed leukemia. Proc. Am. Assoc. Cancer Res. 33 (1992) 211
33. Spriggs, D., E. Stopa, R. J. Mayer, W. Schoene, D. W. Kufe: Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res. 46 (1986) 5953-5958
34. Stahnke, K., J. Ritter, G. Schellong, J. D. Beck, H. Kabisch, F. Lampert, V. Creutzig: Rezidivbehandlung bei akuter myeloischer Leukämie im Kindesalter. Klin. Pädiatr. 204 (1992) 253-257
35. Steinmetz, H. T., V. Diehl, P. D. Wickramanayke: Idarubicin, fludarabine, cytidine arabinoside (ARA-C) and filgastrim (G-CSF) (IDA-FLAG) in the treatment of poor prognosis AML: A phase II trial. Ann. Hematol. 70. Suppl. II (1995) A100
36. Visant, G., P. Tozi, P. L. Zinzani, S. Manfroi, E. Ottaviani, N. Testoni, M. Clavio, A. Cenacchi, B. Gamberi, P. Carrara, M. Gobbi, S. Tura: FLAG (fludarabine + high-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia 8 (1994) 1842-1846
37. Warrell, R., E. Herman: Phase I and II study of fludarabine phosphate in leukemia: Therapeutic effficacy with delayed central nervous system toxicity. J. Clin. Oncol. 4 (1986) 74-79
38. Wiernik, P. H.: Idarubicin in induction therapy of AML. Ann. Hematol. 70, Suppl. II (1995) A99
39. World Health Organization: WHO Handbook for reporting results of cancer treatment. Geneva. WHO Publication 38 (1979)